Healthcare
Raffles Medical Group immune to slowing medical tourism
No decline in foreign patients seen as new wing nears completion.
Raffles Medical Group immune to slowing medical tourism
No decline in foreign patients seen as new wing nears completion.
Singapore ranks higher in global pension index but still lags in adequacy
It jumped three spots to 7th.
Raffles Medical Group's net profit jumps 4% to $16.2m
Thanks to higher healthcare service revenues.
Singapore shells out $3m to boost research on traditional Chinese medicine
The strategy aims to address the issues brought by its ageing society.
Acromec wins $7m deal to construct lab for Tan Tock Seng Hospital
It also secured an additional $1.8m for after sales maintenance.
The race to commercialise biomedical technologies in Singapore
How would the commercial success of biomedical technology help in the fight against diabetes in Singapore?
SMG's earnings poised for a three-fold growth to $7.3m next year on recent acquisitions
Retaining doctors is a major challenge, however.
A quick guide to what Singaporeans expect from aged care services
Almost half refuse to stay in a six to eight-bedded rooms.
Almost 1 in 3 Singaporeans unwilling to send elders to a nursing home
Check out what their preferred alternatives are.
ISEC Healthcare terminates joint venture deal with Haiyen
It continues to look out for opportunities in Vietnam.
Jonathan Joseph Tan resigns as Asiamedic's chief operating officer
His resignation is effective on October 15, 2016.
Ho Han Siong resigns as non-independent and non-executive director
Effective on October 4, 2016.
Mount Elizabeth Novena to add 100 more beds next year
It will increase capacity to 320 beds.
Raffles Medical Group on track to finish Raffles Hospital extension by next year
It plans to add new beds progressively.
China's flourishing telecare sector opens opportunities for drugmakers
China's healthcare poised for double growth by 2025.
Two ways for Singapore to stay ahead of the competition as Asia's healthcare sector booms
The region is poised for a 3- year CAGR of 12.8%.
Growing pain market to bode well for IX Biopharma
It has five drugs under development.
Read Here
Advertise
Sign Up
